LON:GSK GSK (GSK) Share Price, News & Analysis GBX 1,553 +29.50 (+1.94%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 1,521.50▼ 1,557.5050-Day Range 1,498▼ 1,788.5052-Week Range 1,330.19▼ 1,823.50Volume4.97 million shsAverage Volume7.34 million shsMarket Capitalization£63.36 billionP/E Ratio1,424.77Dividend Yield3.86%Price TargetGBX 1,820 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get GSK alerts: Email Address GSK MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside17.2% UpsideGBX 1,820 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.56Upright™ Environmental ScoreNews Sentiment0.31Based on 10 Articles This WeekInsider TradingAcquiring Shares£732,828 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.80 out of 5 stars 3.3 Analyst's Opinion Consensus RatingGSK has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageGSK has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GSK's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GSK. Previous Next 0.8 Dividend Strength Dividend YieldGSK pays a meaningful dividend of 3.38%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 5,504.59%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about GSK's dividend. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.Environmental SustainabilityThe Environmental Impact score for GSK is -1.56. Previous Next 2.4 News and Social Media Coverage News SentimentGSK has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for GSK this week, compared to 6 articles on an average week.Search Interest45 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have bought more of their company's stock than they have sold. Specifically, they have bought £7,328.28 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 1.60% of the stock of GSK is held by insiders.Percentage Held by Institutions44.80% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 1,424.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 1,424.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About GSK Stock (LON:GSK)GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More GSK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSK Stock News HeadlinesJuly 26 at 12:04 AM | finance.yahoo.comGSK Jul 2024 47.000 call (GSK240726C00047000)July 26 at 12:04 AM | bloomberg.comGSK’s Shingles Shot Linked to Delayed Dementia Onset in StudyJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 25 at 2:01 PM | msn.comFort Worth Museum of Science and History encourages kids to be space scientistsJuly 23 at 3:15 PM | ca.finance.yahoo.comGSK Jan 2026 25.000 putJuly 23 at 10:14 AM | markets.businessinsider.comSCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study ReportJuly 23 at 2:02 AM | americanbankingnews.comGSK plc (LON:GSK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 22, 2024 | finance.yahoo.comEMA accepts GSK’s Blenrep MAA for multiple myeloma for reviewJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 21, 2024 | nz.finance.yahoo.comGSK Jul 2024 44.500 callJuly 20, 2024 | marketwatch.comGSK falls Friday, still outperforms marketMay 28, 2024 | finance.yahoo.comCureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSKMay 25, 2024 | marketwatch.comGSK Says Illinois Jury Finds Heartburn Drug Zantac Not Liable for Plaintiff's CancerMay 24, 2024 | markets.businessinsider.comGSK: Court Finds In GSK's Favour In First Zantac Case To Go To TrialMay 23, 2024 | msn.comPotential blockbuster asthma drug met goals in trials, GSK saysMay 23, 2024 | msn.comBoost for GSK as US court rejects woman's claims heartburn drug Zantac caused her cancerMay 23, 2024 | msn.comGSK says its experimental drug reduced asthma attacks with only two doses a yearMay 21, 2024 | finance.yahoo.comGSK’s New Vaccine Kept the Boss in Her Job — and an Activist at BaySee More Headlines Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2020Ex-Dividend for 7/11 Dividend5/16/2024Dividend Payable7/11/2024Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:GSK CUSIPN/A CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees90,100Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,820 High Stock Price TargetGBX 2,100 Low Stock Price TargetGBX 1,585 Potential Upside/Downside+17.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 1.09 Trailing P/E Ratio1,424.77 Forward P/E Ratio9.88 P/E Growth1.19Net Income£4.48 billion Net Margins14.59% Pretax MarginN/A Return on Equity38.78% Return on Assets9.31% Debt Debt-to-Equity Ratio134.34 Current Ratio0.87 Quick Ratio0.73 Sales & Book Value Annual Sales£30.74 billion Price / Sales2.06 Cash FlowGBX 190.66 per share Price / Cash Flow8.15 Book ValueGBX 339 per share Price / Book4.58Miscellaneous Outstanding Shares4,080,000,000Free FloatN/AMarket Cap£63.36 billion OptionableNot Optionable Beta0.27 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Emma Natasha Walmsley (Age 55)CEO & Director Comp: $5.39MMs. Julie Belita Brown (Age 62)CFO & Executive Director Comp: $5.14MMs. Shobie Ramakrishnan (Age 53)Chief Digital & Technology Officer Mr. Tony WoodChief Scientific Officer and Head of R&DMs. Sarah Elton-FarrHead of Investor RelationsMr. James FordSenior VP & Group General Counsel of Legal & ComplianceMs. Sally JacksonSenior Vice President of Global Communications & CEO OfficeMr. David Simon Redfern BSc (Hons) (Age 58)CA, President of Corporate Development Ms. Diana ConradChief People OfficerMr. Philip C. ThomsonPresident of Global AffairsMore ExecutivesKey CompetitorsSophos Group plc (SOPH.L)LON:SOPHGraingerLON:GRISilence TherapeuticsLON:SLNAmryt PharmaLON:AMYTGlobal PortsLON:GPHView All CompetitorsInsidersWendy BeckerBought 446 shares on 6/20/2024Total: £719,844.00 ($1,614.00/share)Julie BrownBought 8 shares on 6/11/2024Total: £12,984.00 ($1,623.00/share)Urs RohnerBought 434 shares on 3/20/2024Total: £721,308.00 ($1,662.00/share)Emma WalmsleySold 139,792 sharesTotal: £231.78 M ($1,658.00/share)Emma WalmsleyBought 8 shares on 2/9/2024Total: £13,296.00 ($1,662.00/share)View All Insider Transactions Should I Buy GSK Stock? GSK Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in GSK plc: GSK's stock price has been trading at a relatively stable level, indicating potential consistency in returns for investors. GSK recently reported strong quarterly earnings, surpassing analyst expectations, which could lead to positive market sentiment and potential stock price appreciation. Analysts have given GSK a "buy" rating, suggesting confidence in the company's future performance and growth potential. GSK has a diversified product portfolio in the pharmaceutical sector, reducing risk associated with dependence on a single product or market. The company's dividend yield, though recently reduced, still offers investors a source of income, albeit at a lower rate. Cons Investors should be bearish about investing in GSK plc for these reasons: GSK's dividend payout ratio is extremely high, indicating that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment for growth. The company's debt-to-equity ratio is notably high, which could pose risks in times of economic downturns or financial instability. GSK's stock price has experienced recent fluctuations, suggesting volatility that may not align with risk-averse investor strategies. Recent insider trading activity, such as the purchase of shares by an insider, could signal uncertainty or lack of confidence in the company's future performance. Analysts have issued a "sell" rating on GSK, indicating concerns about the company's outlook and potential challenges ahead. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 2, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com. GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at GBX 1,450.20 at the start of the year. Since then, GSK shares have increased by 7.1% and is now trading at GBX 1,553. View the best growth stocks for 2024 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 38.78% and a net margin of 14.59%. How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA) and Johnson & Johnson (JNJ). This page (LON:GSK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
